Endolymphatic Hydrops (Meniere's Disease) Tests
Customize your policy alerts
Sign up for Aetna Policy 0571 alerts
Get alerted when Policy 0571 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity and investigational determinations for diagnostic tests used to evaluate endolymphatic hydrops (Meniere's disease), and lists related policies and applicable billing codes; applies to Aetna members and their providers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Diagnostic Tests for Endolymphatic Hydrops (Meniere's Disease)
Medically necessary indication
Covered when ALL of the following are met
Test protocol includes baseline audiometry and repeat audiometry post-ingestion (commonly at ~3 hours); consider side effects (headache, nausea, thirst, diarrhea, emesis, diuresis, dizziness).
Experimental / Investigational
Not covered / Experimental and Investigational
These procedures are considered investigational for the indications listed in this policy and are not supported as standard diagnostic tests.
Evidence-based coverage considerations
Summary of available evidence and guideline stance
Evidence supports MRI as a supplementary test but not as a standalone definitive diagnostic; timing (e.g., during attack) and small sample sizes affect performance.
Tests are emerging and not standardized; use results in the context of clinical assessment.
Combination audiologic measures may modestly improve diagnostic accuracy but available studies are limited in size; routine use is discouraged by guideline recommendation.
Aetna considers dehydration testing (glycerol, urea, or other osmotic diuretics) medically necessary only for members with atypical presentations of endolymphatic hydrops (Meniere’s disease). For indications other than atypical presentations, dehydration testing is considered experimental and investigational because its effectiveness has not been established. The test protocol includes baseline audiometry and repeat audiometry after administration of the osmotic agent; a positive test is defined by the thresholds noted elsewhere in this policy (see definitions/thresholds).
Hydrops-protocol MRI using intravenous gadolinium is described as a potential supplementary tool when clinical diagnosis is uncertain or atypical/secondary causes are suspected, but routine use for early or subtle symptoms is limited. The literature highlights lack of normal control cutoffs, effects of disease duration, small study sizes, variability in MRI sequence parameters and hydrops grading, and concerns about reproducibility across MRI manufacturers; these issues currently limit broader, standardized clinical application of IV‑Gd inner‑ear MRI. Documentation correlating imaging findings with audiovestibular testing and clinical rationale is recommended when used.
Multi‑frequency tympanometry (MFT) has been evaluated as an in‑office, noninvasive test (measuring 2‑kHz probe tone Y‑width) to reflect cochlear pressure changes. In a prospective study the authors observed a high false‑positive rate, modest sensitivity (58.3%) and specificity (66.3%), and no significant differences across study groups; therefore the investigators did not support standardized use of MFT as an additional diagnostic tool for detecting endolymphatic hydrops. A negative MFT result was considered unlikely to reflect hydrops.
To reiterate, dehydration (glycerol/urea) testing performed for indications other than atypical presentations of Meniere’s disease is considered experimental and investigational and therefore not covered. When dehydration testing is performed for atypical presentations, the established positivity criteria (repeat audiometry showing an improvement of ≥10 dB at ≥2 frequencies or ≥12% improvement in speech discrimination) should be used to interpret results.
Guideline recommendations and systematic reviews advise against routine ordering of electrocochleography (ECoG) or vestibular function testing solely to establish a diagnosis of Meniere’s disease. These statements reflect that available tests for endolymphatic hydrops are not standardized, have variable sensitivity and specificity, and therefore should not be used routinely as definitive diagnostic tools without correlation to the clinical presentation.
Recent clinical studies have failed to demonstrate consistent, reliable objective diagnostic performance for frequency‑specific ECoG and related measures. In a 91‑patient (182‑ear) series comparing frequency‑specific action potential latency, traveling wave times, and SP/AP ratios across diagnostic groups, no significant differences were found for AP latency or SP/AP ratio between Meniere’s classification groups, and traveling wave velocity did not prove to be a useful objective diagnostic test. Taken together, these data do not support routine use of frequency‑specific ECoG as a definitive diagnostic measure for endolymphatic hydrops.
Coding and Diagnostic Criteria
| 81406 | Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) |
| 92517 | Vestibular evoked myogenic potential (VEMP) testing; cervical (cVEMP) |
| 92518 | Vestibular evoked myogenic potential (VEMP) testing; ocular (oVEMP) |
| 92519 | Vestibular evoked myogenic potential (VEMP) testing; cervical and ocular |
| 92550 | Tympanometry and reflex threshold measurements [multi-frequency tympanometry] |
| 92567 | Tympanometry (impedance testing) [multi-frequency tympanometry] |
| 92584 | Electrocochleography |
| 69805-69806 | Endolymphatic sac operation |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
| H81.01-H81.09 | Meniere's disease |
| H81.10-H81.13 | Benign paroxysmal vertigo |
| H81.311-H81.399 | Other peripheral vertigo |
| H81.41-H81.49 | Vertigo (including vertigo of central origin) |
| H83.01-H83.2X9 | Labyrinthitis |
| R26.0-R26.9 | Abnormalities of gait and mobility |
| R42 | Dizziness and giddiness |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Recommended for IV-Gd Inner-Ear MRI
Prior authorization is recommended for intravenous gadolinium (IV-Gd) inner-ear MRI when used to evaluate suspected endolymphatic hydrops (Meniere's disease). When requesting advanced imaging, document the audiovestibular correlation and the clinical rationale for why IV-Gd MRI is needed to supplement the evaluation rather than routine testing.
- Affected service: IV-Gd inner-ear MRI (contrast agent A9579 may be billed).
- Include in imaging request: clinical history, audiometric and vestibular test results, and specific rationale linking MRI findings to management decisions.
Dehydration Testing — Medically Necessary Only for Atypical Presentations
Dehydration (glycerol/urea/other osmotic diuretic) testing is considered medically necessary only for patients with atypical presentations of endolymphatic hydrops (Meniere's disease). For other indications, dehydration testing is considered experimental and investigational and is not supported by evidence.
- Baseline audiometric testing must be performed prior to administration of the osmotic agent.
- Repeat audiometry is typically performed at 3 hours post-ingestion (and sometimes at 1 and 2 hours); test positivity: ≥10 dB improvement at 2 or more frequencies (250–2,000 Hz) or ≥12% improvement in speech discrimination.
- Dehydration testing may cause adverse effects (headache, nausea, diarrhea, emesis, diuresis, dizziness) — weigh risks/benefits and document atypical presentation justification.
Step Therapy Requirements
No step therapy or prior authorization step-therapy requirements are described for the diagnostic tests discussed in the source excerpts.
- Provider should follow standard preauthorization processes where explicitly recommended (e.g., IV-Gd MRI) but there are no step-therapy sequences required for testing.
Documentation Required for IV-Gd MRI
Document the clinical correlation and rationale when ordering IV-Gd inner-ear MRI to support medical necessity and prior-authorization requests.
- Include: presenting symptoms, laterality, audiovestibular test results (audiometry, ECoG, VEMP, caloric testing as available), prior interventions, and how MRI results will change management.
- If MRI is being used because other evaluations are inconclusive or to evaluate atypical/secondary/embryopathic EH, state this explicitly in the request.
Clinical Evidence and Study Findings
Clinical studies summarized in the policy provide context for the diagnostic performance and limitations of ECoG, multi-frequency tympanometry (MFT), and IV-Gd MRI; include these data in clinical decision-making and documentation when relevant.
- Use study limitations (sample size, lack of controls, timing relative to attacks, disease duration) to justify or temper the use of tests in documentation.
- Do not rely on ECoG or MFT as routine definitive diagnostic tests; reference guideline recommendations against routine use of ECoG for establishing MD diagnosis.
Operational Notes / Not Applicable Content
Not applicable: the source excerpts do not specify discrete authorization triggers, billing denial codes, or exact stepwise authorization workflows beyond the IV-Gd MRI recommendation and the medical necessity criteria for dehydration testing.
- Providers should follow payer-specific prior authorization procedures when recommended and include the documentation elements noted above.
- Routine testing (ECoG, vestibular testing) is discouraged for establishing diagnosis per guidelines and may not be supported without clear clinical justification.
Background and Rationale
Endolymphatic hydrops (Meniere's disease) is a clinical syndrome characterized by episodic vertigo, fluctuating sensorineural hearing loss (often low‑frequency), tinnitus, and aural fullness. Diagnostic testing options described in the literature include dehydration (glycerol/urea) testing, electrocochleography, vestibular tests (VEMP, VHIT), IV‑Gd inner‑ear MRI, and multi‑frequency tympanometry; however, many of these tests lack standardization, have variable sensitivity/specificity, and are best used to supplement—rather than replace—careful clinical assessment. When advanced tests such as IV‑Gd MRI are used, results should be interpreted in the context of clinical findings and audiovestibular testing due to limitations related to technique, timing, and reproducibility.
Definitions and Test Descriptions
Policy Revision History
Policy originally effective on 2001-11-09.
Policy last reviewed on 2023-08-11.
Next scheduled review on 2024-06-13.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.